

# Angiogenesis: A Key Target in Oncology

## Angiogenesis: A Key Target in Oncology

Barcelona, Spain

Friday, May 4 – Saturday, May 5, 2007

### Course Objectives

This course will provide the background for oncologists to understand the basic science and the clinical achievements in angiogenesis related cancer therapy.

This is intended to be a practice-oriented course, helping decision-making processes for the clinician. Participants will have an opportunity to discuss patient case studies and interact with experts, as well as receive updates on the latest data and advances in this field.

*A teaching course in cooperation with the EORTC-GI Group.*

*This course has been approved for CME by ACOE and will also be AMA Category Credit CME approved. Approval where needed by National CME organizations can also be requested.*

Each participant will receive a certificate of attendance stating that he/she attended the entire course. The certificate of attendance will be distributed only at the end of the meeting, after a learning assessment test.

### Course Organizer

ETICHO  
(European Training in Clinical Hematology and Oncology)  
info@eticcho.org

### Target Audience

Physicians and other Healthcare Professionals

### Official Language

English – no simultaneous translation will be available

### Support from

Roche, Medigene, Pfizer

### Chairman

**E. Van Cutsem**

### Scientific Course Co-ordinator

**M. Aapro**

*The field of angiogenesis has evolved from theory to practical clinical application. The initial successes promise that this area will become very important for cancer patient care. There are many questions that will need evaluation, and EORTC-GI Group is looking forward to these developments. We wish great success to this meeting, organized in collaboration with several distinguished members of EORTC-GI Group.*

Prof. E. Van Cutsem

### Venue

Hotel Hilton Diagonal Mar  
Passeig del Taulat 262-264  
08019 Barcelona, Spain

Auspices of UICC are requested.

*In collaboration with  
the EORTC GI Group*



# Angiogenesis: A Key Target in Oncology

## FRIDAY MAY 4, 2007

Registration opens at 10:00 am in Foyer of room

Lunch buffet available from 12:00 noon

### Welcome

13:30 – 13:40 *Welcome & Introduction* Eric Van Cutsem,  
Matti Aapro

### Keynote Address

13:40 – 14:20 *What is Angiogenesis in Relation to Cancer  
Developing Bevacizumab* Bob Kerbel

### 14:20 – 16:00 **Session I: Understanding Angiogenesis – Clinically Relevant Basic Data**

*Each presentation is preceded and followed by one interactive question using a keypad*

14:20 – 15:00 *The Role of VEGF in Cancer Development* Kari Alitalo

15:00 – 15:30 *Do We Know the Molecular Markers That Help Us to  
Determine Who Benefits from Angiogenesis Inhibitors?* Emile Voest

15:30 – 16:00 *Coffee Break*

### 16:00 – 17:30 **Session II: Angiogenesis – Perspectives for Surgical and Radiation Oncology**

*Each presentation is preceded and followed by interactive questions using a keypad*

16:10 – 16:35 *Surgical Aspects When Treating with Anti-angiogenesis Agents* Oliver Stöltzing

16:35 – 17:00 *Imaging and Angiogenesis* Pat Price

17:00 – 17:20 *Can We Combine Angiogenesis Inhibitors with Radiotherapy?* Christopher Willett

17:20 – 17:30 *Summary and Closure for the Day*

20:00 *Buses depart from hotel lobby to Course Dinner*

## SATURDAY MAY 5, 2007

### 08:30 - 10:30 **Session III: Clinical Usage in Colorectal and Breast Cancer**

*Each presentation is preceded and followed by interactive questions using a keypad*

08:30 - 09:00 *Clinical Management of Anti-Angiogenesis Drugs* Herbert Pinedo

09:00 - 09:45 *The Role of Anti-Angiogenesis Agents in the Treatment  
of Colorectal Cancer* Eric Van Cutsem

09:45 - 10:30 *The Role of Anti-Angiogenesis Agents in the Treatment  
of Breast Cancer* tbc

10:30-11:00 *Coffee Break*

### 11:00 – 13:00 **Session IV: Clinical Usage in Lung Cancer and Other Cancers**

*Each presentation is preceded and followed by one interactive question using a keypad*

11:00 - 11:45 *The Role of Anti-Angiogenesis Agents in the Treatment of NSCLC* Enriqueta Felip

11:45 - 12:10 *Anti-Angiogenesis in Prostate Cancer – What is New?* Joaquim Bellmunt

12:10 – 12:30 *The Role of Anti-Angiogenesis Agents in Pancreatic Cancer* Michel Ducreux

12:30 – 12:50 *Positioning Anti-angiogenic Drugs in Renal Cell Carcinoma* Ahmad Awada

12:50 – 13:10 *Gastric Cancer – How to Position Anti-Angiogenic Drugs* Josep Tabernero

13:10 – 13:30 *Learning Assessments: attendees to fill in their evaluation forms  
and answer 15 questions based on the course.  
Certificates will be given ONLY after forms are completed.*

13:30- 14:30 *Lunch buffet and certificate delivery*